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Abstract
Obesity is a mounting problem in America today. One major concern about obesity is that it is a risk factor for type 2
diabetes, a disease that impairs insulin sensitivity and secretion. This interferes with blood glucose levels and can cause
hyperglycemia, which is when there is too much circulating glucose in the blood. Ghrelin, an amino acid peptide responsible for appetite stimulation and energy balance, plays a direct role in insulin secretion and glucose metabolism. In many
experiments, elevated ghrelin levels are associated with decreased insulin secretion from pancreatic islet cells. Although
ghrelin concentration is decreased in obese individuals and diabetics, researchers attempt to use the ghrelin system as a
treatment option for these people. It seeks to accomplish this by regulating the ghrelin produced by the body, diminishing
its activity, affecting its receptor, the growth hormone secretagogue receptor (GHS-R1a), and by targeting ghrelin directly.
Studies observed these methods’ effects on insulin secretion and sensitivity as well as blood glucose concentration. The
octanoylation of ghrelin, which activates it, is catalyzed by ghrelin Oacyltransferace (GOAT). Therefore GOAT inhibitors
are one way of minimizing ghrelin’s effects on metabolism. Additionally, cAMP concentrations decrease in islet cells of the
pancreas in the presence of ghrelin. Using cAMP analogs can counter ghrelin’s consequences as well. On the other hand,
targeting the GHS-R1a receptor with an antagonist can also help enhance insulin secretion. Another research option
entails using immunoneutralization to build antibodies against endogenous ghrelin. Lastly, studies have examined ghrelin
knockout models in mice, by deleting the ghrelin gene, to examine the results that the lack of ghrelin has on insulin-glucose
metabolism. Each of these methods has been proven to affect insulin and glucose metabolism. Further advances in the
clinical application of these methods may lead to viable treatment options for obesity and diabetes.
Introduction
A big problem facing the world today is the rise of obesity.
According to the CDC, approximately one third of the American
adult population is obese. Obesity is characterized by a Body
Mass Index (BMI), of 30 or higher, while healthy weight BMI is in
the range of 18.5-24.9 (CDC, 2012). One possible con-sequence
of obesity is the development of type 2 diabetes. Diabetes is a
disease characterized by elevated glucose levels as a result of
insufficient insulin production or a malfunctioning insulin system.
Of the Americans population 29.1 million or 9.3%, had diabetes
in 2012. This number was an increase from 2010 when the statistics were 25.8 million and 8.3% (American Diabetes Association,
2014). In type 1 diabetes mellitus, the β cells of the pancreas that
are responsible for producing insulin are destroyed. In the absence of insulin, these individuals are at risk for hyperglycemia, or
dangerously elevated blood glucose levels.Type 2 diabetes usually
has a later onset. People with type 2 diabetes experience insulin
resistance so that the insulin does not help glucose enter the
body cells. Eventually the body stops producing insulin altogether
(CDC, 2014). Most cases of diabetes, 90-95% are type 2 diabetes.
Statistics show that 90% of cases of type 2 diabetes in western
countries can be attributed to excess weight gain or obesity.
Improving glucose tolerance while losing weight is the aim of
new treatments for diabetes. Examining the effects the hormone
ghrelin has on glucose metabolism can be a valuable therapeutic
option (Rudolph, et al. 2007). Ghrelin is a 28 amino acid peptide
hormone that plays a role in many different body functions. It is
the endogenous ligand for the growth hormone secretagogue
receptor (GHS-R) and has been proven to increase growth hormone secretion.Additionally, ghrelin is known as an orexigenic, or
appetite-stimulating hormone, and is also responsible for energy
bal-ance. It is produced predominantly in the stomach but is also

produced in other places including the pancreas. One important
function ghrelin serves is the ability to control insulin release
from β cells of the pancreas. In the presence of ghrelin, insulin
secretion is reduced, and blood glucose concentration increases.
Research shows the effect of ghrelin on pancreatic islet β-cells.
Ghrelin suppresses insulin secretion from β-cells by interfering
with the K and Ca2+ channels that are stimulated by glucose
metabolism. Obese individuals and diabetics have lower levels of
plasma ghrelin than lean individuals. It is reasonable to suggest
that this may be a regulated response in order to minimize the
ghrelin activity that reinforces obesity. Subsequent research implicated possible regulation of ghrelin to treat obesity and diabetes. Since insulin levels are decreased in the presence of ghrelin,
investigation of techniques to reduce or diminish the effects of
ghrelin is in effect. Various treatment options that have undergone research and experimentation show posi-tive outcomes
in regard to treating diabetes and obesity. Many techniques that
influence ghrelin’s role in decreased insulin secretion are still in
the experimental phase but may eventually be effective to treat
diabetes and obesity. Ghrelin’s effects on insulin sensitivity are
also being explored. Can regulation of ghrelin serve as a possible
treatment option for diabetes and obesity?

Methods
The research obtained about ghrelin’s effects on the metabolism
of diabetics and obese individuals was collected from a variety
of sources. The majority of articles were collected using Touro’s
library to access databases such as Pubmed, ProQuest and more.
Additionally, other articles were found by searching Google
scholar for relevant journals on the topic. After reviewing numerous articles on ghrelin’s effects on obesity and diabetes, evidence
was compiled to answer the research question.

48

Regulation of Ghrelin

Discussion
Ghrelin and its forms:
Ghrelin is a 28-peptide amino acid that is produced mainly in the
stomach. This hormone is responsible for signaling hunger and
maintaining an energy balance. Acylated ghrelin, or acyl ghrelin,
the active form of ghrelin consists of noctanoylation on the
third serine. This form of ghrelin is able to bind to the GHS-R1a,
enabling it to have a biological effect in areas such as growth
hormone secre-tion and glucose metabolism. However, most of
our plasma circulating ghrelin is unacylated ghrelin, or des acyl
ghrelin, which has been discovered to have biological effects as
well (Kiewiet, et al. 2009).
Figure 1

The effects of each form of ghrelin on insulin concentration and
sensitivity has been studied. Acylated ghrelin (AG), the active
form of ghrelin has been found to be responsible for decreased
insulin levels, while unacylated ghrelin’s (UAG) affects are being
studied. It has been noted that ghrelin levels have a preprandial
increase and a postprandial decrease indicating its role as an appetite stimulant (Kiewiet, et al. 2009). The hormone insulin acts
in the opposite way, so investigators seek to explain the relationship between the two. Some studies examined the effects of
AG and UAG on the insulin metabolism. Findings were that AG
stimulated glucose release by hepatocytes, while UAG inhibited
these effects. In addition, in an experiment done with adult-onset
growth hormone-deficient patients, AG was found to decrease
insulin sensitivity, and coinjection of UAG countered the effect.
Thus, the circulating plasma ghrelin’s two forms act in contrasting
ways (Ukkola, 2009). An experiment was conducted in order to
isolate the actions of AG and UAG. Subjects were administered
a combination of AG and UAG and then each form of ghrelin on
its own. The subject group consisted of 8 morbidly obese female
Caucasians. The mean age was 45.4± 10.3 in the range of 28-62
years old. The average BMI of the subjects was 42.4± 4.8 kg/m2 .

This experiment was a repeated measures design in which each
of the 8 subjects received all the experimental conditions with
a two-week break in between. Ghrelin was administered after
overnight fasting conditions after a saline infusion. The three experiments were: administration of 200 µg of UAG on its own,
administration of 100 µg of AG together with 100 µg UAG, and
a placebo. Subjects were then given a 595 kcal breakfast, a similar
lunch three hours later, and then they were free to eat what they
pleased until midnight. Blood samples were collected to measure
the total ghrelin, glucose, and insulin concentrations. After the
first hour of administration, while subjects were fasting, administration of UAG on its own did not change insulin levels or glucose concentrations, nor did it differ from the placebo. Receiving
the combination of UAG and AG resulted in significantly decreased insulin levels as compared to UAG administration alone
and the placebo (58.2 ± 6.3% insulin concentration when AG and
UAG were administered combined, compared to 91.8 ± 3.0%,
the insulin concentration when UAG was administered alone).
This experiment tested for insulin sensitivity using the glucose
to insulin ratio. The results indicated an almost 50% decrease in
insulin levels and almost no change in glucose concentration.This
demonstrated the effect of UAG to improve insulin sensitivity
when administered along with the AG that lowered the insulin
levels. Also, subjects with a smaller AG:UAG ratio possessed
increased insulin sensitivity indicating the combination effect of
coinjection of AG and UAG.This may lead to a possible treatment
for diabetes for many diabetics have problems with insulin sensitivity. However, further research is needed to exactly determine
insulin sensitivity, for the glucose-insulin ratio does not consider
secretion, distribution and degradation of insulin (Kiewiet, et al.
2009).
However, a recent study tested the effect of AG in combination
with UAG on insulin and glucose metabolism. Healthy volunteers
were given pharmacological doses of AG and UAG as a bolus
and at 210-minute intervals under fasting conditions and intravenous glucose administration. However, The UAG did nothing
to plasma insulin levels after AG decreased them. This study did
not examine but encourages further study on insulin sensitivity
following AG and UAG administration (Barazzoni, 2014). Previous
research tested the effects of ghrelin on inulin sensitivity by using
the insulin-glucose ratio. Although the insulin levels stayed the
same, the glucose levels decreased indicating greater insulin sensitivity (Kiewiet, et al. 2009). Although this may not give the most
reliable results because it does not consider other factors that
can contribute to insulin sensitivity, it is a start in observing the
effect that UAG has on insulin sensitivity. Nevertheless, further
research is needed to confirm this relationship.

Insulin Sensitivity
Although it may be hypothesized that obese individuals have
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elevated ghrelin levels contributing to their obesity, on the contrary, obese individuals have lower ghrelin concentrations than
normal. According to a study obese patients’ plasma active
ghrelin levels compared to lean subjects were 180 ± 18 vs. 411
± 57 pg/ml. Serum total ghrelin levels differed from 3650 ±408
in obese patients and 5263 ±643 pg/ml in lean subjects. Ghrelin
levels were correlated with insulin resistance that was calculated
using the HOMA approach which is: insulin (micro-units/milliliter)
× blood glucose (milllimoles/liter)/ 22.5 (Marzullo, et al. 2003).
Similarly, in a different study, lower ghrelin levels were found in
obese subjects. This study, shows the correlation between body
fat and circulating ghrelin levels after obese and lean subjects
were fed a weight maintaining diet and abstained from exercise
two days. The results indicated that the obese subjects’ ghrelin
levels were 32% lower than the lean subjects’. Additionally, a
negative correlation was found between ghrelin concentration
and body fat (r = -.45). Insulin was also negatively correlated to
ghrelin concentration (r = -.45) (Tscöp, et al. 2001). Since ghrelin
is responsible for energy balance and homeostasis, this study is
consistent with present knowledge. Obese individuals have stable
energy levels so the body lowers the ghrelin response. However,
although the circulating ghrelin levels are minimized, its effects on
insulin and body fat are still present.
Studying children with type 1 diabetes mellitus (T1DM) indicated
lower levels of total ghrelin in comparison to healthy subjects.
Also, higher levels of AG contributed to lower insulin levels and
greater insulin resistance. Therefore, a possible way the body
protects diabetics from hyperglycemia can be the decreased concentration of circulating ghrelin. Insulin therapy after four months
elevated ghrelin levels in twenty children with T1DM (Ukkola,
2009). This can indicate the body considering lower ghrelin levels
unnecessary due to the insulin therapy.
Although we can understand how insulin resistance is a problem
in diabetic patients, obesity can contribute to insulin resistance as
well. One way in which obesity contributes to insulin resistance
is through the immune system’s activation by obesity. Adipose
tissue macrophages produce pro-inflammatory cytokines that
can lead to insulin resistance by blocking insulin action in adipose
tissue, skeletal muscle, and liver. Therefore, ghrelin as a possible
therapeutic option can improve both diabetics and obese individuals’ health (Ota, 2014).

Ghrelin’s Metabolic Effects
An experiment examined ghrelin levels in lean, obese, diabetic
and nondiabetic subjects. Blood samples were collected after
overnight fasting and again after monitored eating. Compared
to normal weight subjects, mean plasma ghrelin concentrations
were 225% for those with anorexia nervosa and 68% for obese
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subjects. A negative correlation exists between BMI and plasma
ghrelin concentration. The body maintains homeostasis by decreasing ghrelin levels in the presence of positive energy balance.
When the body has excess energy from nutrition, the ghrelin levels are decreased to postpone hunger.This justifies the postprandial, or after eating a meal, decrease of ghrelin levels (Shiiya, et al.
2002). Ghrelin’s effects on feeding and energy balance refer to
the ghrelin produced in the stomach; however, the pancreas also
produces ghrelin contributing to glucose metabolism. Ghrelin
is an insulinostatic hormone, meaning it controls the release of
insulin. Ghrelin levels were compared from the pancreatic vein
that leaves the pancreas and the pancreatic artery that brings
new blood to the pancreas. Results showed 8 times the amount
of ghrelin levels in the pancreatic vein, indicating the pancreas
produces that ghrelin (Yada, et al. 2014).The GHS-R1a, the ghrelin
receptor, is located on pancreatic islet cells. Ghrelin binds to the
receptor and decreases insulin release from the cell and elevates
blood glucose concentrations. When glucose concentrations rise
from 2.8 mM to 8.3 mM, insulin release from β cells is stimulated.
The intensification of Ca2+ concentrations, stimulated by glucose
metabolism is a crucial step in insulin secretion. However, insulin
release is weakened when ghrelin is exogenously administered at
a high concentration of 10 nM. Ghrelin suppresses the peaks of
Ca2+ by increasing amplitudes of Kv currents that block the influx of Ca2+ ions into the cell thereby slowing down the process
of glucose-induced insulin release (Yada, et al. 2008).
Figure 2

The binding of ghrelin to GHS-R reduces cAMP expression and increases the K+ current.This slows down the influx of Ca2+ into the
cell, leading to a decreased insulin secretion response to glucose
metabolism. (Yada, et al. 2014)
Research has proven that ghrelin’s effect on the Kv channels result from decreased cAMP levels. cAMP, cyclic AMP (adenosine
monophosphate) signaling plays one of the most vital roles in insulin secretion from beta cells (Kashima,et al. 2001). Ghrelin uses
G-protein Gαi2 to obstruct the cAMP response to glucose metabolism. cAMP activates PKA, protein- kinase-A, and suppresses
Kv currents in islet cells. Since the insulinostatic effect of ghrelin
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occurs through the cAMP pathway, one possible way to minimize
it is by presenting cAMP analogues along with ghrelin. One molecule used in testing the effects of cAMP analogs on insulin secretion is 6-Phe-cAMP. In the presence of cAMP analogs, ghrelin has
no effect on insulin secretion. Hence, by reinstating the cAMP
activation pathway in the presence of ghrelin, diabetics can experience enhanced insulin secretion (Dezaki, et al. 2011). This study
demonstrates a new remedial approach to reducing ghrelin’s effects. cAMP analogs may aid diabetes by enhancing insulin secretion in pancreas islet.

Ghrelin Antagonism
Since type 2 diabetics do not have enough insulin, anti-ghrelin
treatments can enhance insulin secretion. In obesity, insulin resistance is a problem, so eliminating ghrelin can produce a positive
effect on hyperglycemia. Ghrelin’s affects on insulin and glucose
metabolism, food intake, and body weight all need to be assessed
in order to determine if antagonism of ghrelin can relieve symptoms of diabetics and obese individuals. One popular method
used to remove ghrelin’s affects is by antagonism of the GHS-R.
If the receptor does not accept ghrelin, it has no effect on the
pancreatic islets. In an experiment using fasted mice, ghrelin receptor antagonists [D-Lys3]-GHRP-6 enhanced insulin secretion
and lowered blood glucose levels. This research indicated that a
ghrelin blockade increases insulin release to help maintain normal
glucose concentrations (Yada, et al. 2008). Experiments done with
gastrectomized mice, that lack stomach-derived ghrelin, show the
role of pancreatic ghrelin in the insulin response. After GHS-R
antagonist was administered, both groups of mice showed the
same increased insulin response. This proves that the pancreatic
ghrelin is responsible for these effects. Therefore, targeting the
GHS-R can be a therapeutic approach in enhancing insulin secretion (Dezaki, et al. 2006). Administering intra-peritoneal ghrelin
antagonist to mice also decreased food consumption (Asakawa,
et al. 2003). These findings can be beneficial in aiding obese individuals control their food intake.
Additionally, an experiment done on mice implied ghrelin’s effects
on body weight, insulin levels, and blood glucose concentrations.
Injection of ghrelin twice a day for five days increased body
weight in mice compared to the control. Depending on the diet
and whether the mouse received ghrelin or saline, determined
the increase in body weight. For example, one group of mice
were fed a high fat diet and given saline. These mice exhibited a
.60 g/day increase in body weight, while those fed a high fat diet
with ghrelin had a .92 g/day increase. Serum cholesterol and insulin levels increased and glucose concentration increased as well.
The same experiment tested how ghrelin antagonist, [D-Lys3]GHRP-6, affected the same factors. After 7 days of administration to obese mice, weight gain, fat pad mass, and blood glucose
concentrations decreased (Asakawa, et al. 2003). This study does

not seem to be consistent with other research that has linked
elevated ghrelin to decreased plasma insulin secretion; but a
moderate increase in glucose concentration was observed. This
can indicate a case of insulin resistance instigated by an increase
in free fatty acids (FFA) that are known to contribute to insulin
resistance. GHS-R antagonists increased insulin sensitivity and
reduced glucose levels. In addition, it simultaneously decreased
FFA concentration aiding in fostering insulin sensitivity (Asakawa,
et al. 2003).
One class of drugs that is being studied as possible ghrelin receptor antagonists are quinazolinone derivatives. In the lab, quinazolinone derivative 1 was discovered to have affinity to GHS-R1a.Yet,
it was found that the molecule had agonistic binding to the receptor rather than the desired antagonistic affect. Alkylation of the N
group on the molecule altered its functionality by transforming
it into a GHS-Rla antagonist. Piperdine-substituted quinazolinone
derivatives that are phenyl or phenoxy substituted were found to
act as GHS-R antagonists (Del-porte, 2011).
Figure 3

Alkylated

12

In a structure-activity relationship study, many derivatives of the
compound were tested for their effects in vivo. Two quinazolinone compounds that were used for study were compounds
26 and 43. These antagonists were administered at doses 3, 10,
and 30 mg/kg. While compound 26 lowered body weight at the
10 mg/kg dose, compound 43 only was effective at 30 mg/kg.
Compound 26 at 30 mg/kg is known as the first orally administered GHS-R antagonist possible to induce weight loss in animals.
This renders it a feasible way to treat obesity, a leading cause of
diabetes. Compound 26 administered at the highest dose had
similar effects to an anti-obesity drug that is still under evaluation
by the FDA, CB1 antagonist rimonabant, 5-(4-choophenyl-1-(2,4dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide. This study also tested glucose tolerance. Both compounds decreased glucose excursion by around 20%. However,
the cause be-hind these decreased blood glucose levels, was
not tested for. The study would like to go further in confirming
that this result from the GHS-R antagonist stemmed from an
enhanced insulin secretion (Rudolph, et al. 2007). This research
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brings practical application of a drug that may be available to help
treat obesity and diabetes. As a receptor antagonist, it minimizes
ghrelin’s insulinostatic effects and enhances glucose metabolism.

Immunoneutralization
Immunoneutralization of ghrelin also is a potential method of
enhancing insulin secretion. Creating a vaccine to stimulate antibody production against acylated ghrelin may be a viable treatment for obese individuals. However, when a trial was conducted
using a CYT-009 Ghr Qb vaccine, antibodies were developed, but
weight stayed the same (Delporte, 2011). In another instance,
mice were immunized against ghrelin to produce an antibody
response. After being fed identical diets, the rats with more
ghrelin-specific antibodies gained less weight per calorie ingested.
Since their food intake did not vary from other control mice,
this experiment shows that ghrelin produces a metabolic change
rather than feeding changes. However, ghrelin has been known
to increase feeding in a high-fat diet, these mice were given lowfat, less appetizing meals. This could be a factor that might have
influenced the ghrelin-vaccinated mice’s feeding habits, so the reliability of their conclusion is questionable. Additionally, there can
be possible draw-backs to this course of treatment. Long-term
or other side effects of eliminating ghrelin are unclear. It may
have possible ramifications on energy balance that is regulated by
ghrelin.The absoluteness of inactivating ghrelin by use of antibodies is also irreversible, unlike ghrelin receptor antagonism that
can be stopped when undesired effects occur. Another obstacle
that we may be facing with immunoneutralization is the negative
feedback loop of the body producing more ghrelin to compensate for lack of ghrelin signals. Although the immediate results of
an anti-ghrelin vaccine may look promising, further research is
needed to con-firm the safety and reliability of this method to
reduce body weight. Controlling the immune response can keep
ghrelin antibodies from getting out of hand (Carl-son, Cummings,
2006). However, until research can safely develop and monitor
such a vaccine, it would be best to put this method on hold.

Ghrelin Knockout
An alternative to a ghrelin vaccine is the ghrelin knockout model.
The ghrelin gene is deleted from rats and they are then monitored for feeding habits, metabolism, weight gain, and glucose
concentration. One point to remember is the unknown effects
of ghrelin’s complete absence from the body. In one experiment,
ghrelin’s effects on insulin secretion were tested using ghrelin
knockout mice. In particular, glucose-induced insulin release was
higher in knockout mice. On the contrary, basal insulin levels
remained the same in knockout and wild-type mice. Therefore,
ghrelin knockout mice had improved insulin responses to glucose.Afterwards, an insulin tolerance test (ITT) was given to both
groups of mice. No significant differences were found between
them.The experiment advanced to testing the effects of a high-fat
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diet, known to increase glucose concentrations. When fed a high
fat diet, blood glucose levels increased in wild-type mice, and no
in-crease was identified in the knockout mice. This can be attributed to enhanced insulin secretion in response to elevated
glucose levels. After the wild-type mice did a glucose tolerance
test (GTT), mice with a high-fat diet showed higher glucose concentration levels compared to a control diet, implicating glucose
intolerance. On the other hand, the ghrelin knockout mice exhibited no difference in glucose tolerance between the high-fat diet
and the control group. However, there was an increased insulin
response in the mice fed a high-fat diet (Dezaki, et al. 2006). This
research shows ghrelin’s role in glucose-insulin metabolism. In
the ab-sence of ghrelin, increased insulin levels and improved glucose tolerance were found. Although ghrelin knockout cannot be
done to humans, it serves as an indication of ghrelin’s metabolic
effects. Regulating ghrelin levels in obese people can possibly improve their body weight and glucose tolerance.

GOAT
Ghrelin O-acyltransferase is a membrane-bound O-acyltransferace.
It catalyzes the octanoylation of ghrelin allowing it to be acylated
and able to connect with the GHS-R1a receptor. Since it catalyzes ghrelin to be in its active form, one idea is to target GOAT
to slow the process of the body producing acylated ghrelin. In
GOAT knockout models, there is no acylated ghrelin found circulating (Pulk-kinen, et al. 2010). As discussed earlier, studies show
that unacylated ghrelin counteracts acylated ghrelin’s effect on
insulin, and did nothing to insulin metabolism when administered
on its own (Kiewiet, et al. 2009). So, inhibiting GOAT action can
minimize the effects that acylated ghrelin has on insulin and glucose metabolism.
One method studied to inhibit GOAT is the administration of
GO-CoA-Tat in mice. The GHS-R binding property of ghrelin
is determined by the octanoylation on serine 3, making it acyl
ghrelin. This inhibitor was found to be most active in binding to
GOAT. After administering GO-CoA-Tat to mice at a 40 mg/kg
dose, acyl ghrelin levels decreased while des acyl ghrelin levels
remained unchanged. Additionally, after 1 month, weight gain
due to decreased fat mass was assessed in the treated mice.
Interestingly, no difference in weight was found compared to
ghrelin knockout mice. This indicates that GOAT inhibition may
have similar effects to ghrelin knockout. The mice’s response to
glucose was measured to observe the effects of GO-CoA-Tat.
The insulin response was in-creased and blood glucose levels
subsequently decreased. This did not occur in ghrelin knockout
mice thereby reinforcing the mechanism of GOAT inhibition to
prevent ghrelin’s acylation (Taylor, et al. 2012). Additionally, use of
this GOAT inhibitor may be a better option than using a ghrelin
antagonist. Some advantages that a study done by Barnett et al.
in 2010 explains that GO-CoA-Tat does not need to cross the
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blood brain barrier unlike the GHS-R antagonist which targets
receptors in the brain as well. Additionally, there is no feedback
of the body trying to compensate by producing extra acylated
ghrelin to bind to the receptors. Another reason given is that
targeting an enzyme like GOAT may be safer than targeting a
widespread receptor (Barnett, et al. 2010). However, GOAT is
still being studied and its use in treatment is not yet confirmed.
Further experimentation would need to be done to examine the
viability of such a method of treatment in humans, and the possible negative side effects of a drug using this mechanism.
Figure 4

Legend
AG: Acylated ghrelin UAG: Unacylated ghrelin
GHS-R: Growth hormone secretagogue recep-tor
GOAT: Ghrelin O-acyltransferace
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